CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long ...

Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome. That's welcome news.

This article explores sex differences in the prevalence and outcomes of CIDP, and underlying factors contributing to the male predominance. Chronic inflammatory demyelinating polyneuropathy (CIDP) and ...

Another Caterham special edition? Been a few of those lately. Missed the headline, did you? It might look like a Seven and quack like a Seven, but this is in fact a GBS Zero, an altogether ...

Pune continues to be plagued by Guillain-Barré Syndrome (GBS) worries, after the 12th suspected GBS death was recorded in Pune district last week. The Pune Municipal Corporation (PMC) survey ...

Dr Jadhav informed that of the new GBS patients, two reportedly consumed PMC-supplied water whereas the third consumed water purchased locally While Pune has witnessed a sudden increase in ...

Pune reported a suspected Guillain Barre Syndrome death on Friday, a fortnight since the last casualty due to the disease. The 38-year-old man is a resident of Manjari on Pune Solapur road and was ...

This disrupts the transmission of signals responsible for muscle movement and sensory functions, causing muscle weakness, tingling sensations and, in severe cases, paralysis of the limbs or facial ...

An ongoing open-label, single arm, POC study is evaluating ANX1502 in patients with cold agglutinin disease (CAD) for up to four weeks to evaluate tolerability, pharmacokinetics, pharmacodynamic and ...

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License ...